top of page

GPCR Retreat Program

Interrogating Multiscale Receptors Functions in Space

Interrogating Multiscale Receptors Functions in Space

Date & Time

Saturday, November 4th / 10:35 AM


Coming Soon

About Martin Beaulieu


Dr. Beaulieu received a Ph.D. in Neurological Sciences from McGill University and completed his post-doctoral training at Duke University. Prior to his recruitment Dr. Beaulieu was an associate professor and Canada Research Chair (Tier2) in the Department of Psychiatry and Neuroscience at Laval University.

Dr. Beaulieu’s research is aimed at understanding how cellular and molecular mechanisms regulated by psychoactive drugs intersect with genetic risk factors for mental illnesses such as schizophrenia, depression, and bipolar disorder. Dr. Beaulieu has pioneered work establishing a role for Beta-arrestin signaling in the brain in vivo and has established its importance in D2 dopamine receptors (D2R) functions. These receptors belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development. In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia and bipolar disorders. Work by the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar disorder therapy target signaling mechanisms regulated by dopamine receptors, thus providing a framework to understand how different drug classes can engage overlapping cellular mechanisms to exert their action. The Beaulieu group is presently investigating how cell surface express proteins can act as allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development of new pharmaceutical agents.

Translational validation is important to validate findings obtained from experimental models research and bridge the gap between bench and bedside. Working in collaboration with geneticists, the Beaulieu-Lab has identified interactions between cellular mechanisms engaged by D2R and psychiatric drugs with genetic risk factors implicated in schizophrenia by large whole-genome association studies (GWAS) in humans. These investigations have led to the identification of an RNA binding protein (FXR1P) involved in the regulation of protein synthesis as a potential downstream effector of the action of mood stabilizers and other psychoactive drugs.

In addition to basic research, the Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology.



Martin Beaulieu on the web


Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec

Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec

22nd GPCR Retreat Sponsored by


Canada Research Chairs
U of Ottawa
Canadian Institutes of Health Research
Bristol Myers Squibb
InversAgo Pharma
Monica Seger and Family
Duke University, Dept. Cell Biology
OHRI Neurosciences Program
University of Toronto Mississauga
Domain Therapeutics NA Inc.
Otsuka Pharmaceuticals
McGill University, Dept. Pharmacol & Exp Ther
University of Toronto, Dept. of Physiology
Hotchkiss Brain Institute,University of Calgary
Université de Montréal, VP Office
Find Therapeutics
University of Toronto, Dept. Pharmacol & Toxicol
Deep Apple
University of Illinois at Chicago (Mark Rasenick)
uOttawa, VP Research Office
American Society of Pharmacology and Experimental Therapeutics
University of Western Ontario Schulich School of Medicine & Dentistry
Université de Sherbrooke, Dept. Pharmacology-Physiology
Research Institute McGill Univ. Health Centre
adMare Bioinnovations
Université de Montréal, Faculty of Medicine
Université de Sherbrooke, Institut de Pharmacologie
Science Signaling
Montana Molecular
uOttawa, Dept. Cellular & Molecular Medicine
uOttawa, Dept. Biochem Microbiol Immunol
uOttawa, Behavioral & Physiology Core